ZOARZOARConsumer Cyclicals · Drug Manufacturers - General

ZOAR Stock Forecast: Zoar Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.38
−22.48% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$653.4M
Ticker Nerd rank
18/ 100
Median analyst target
—
Analysts covering
—
Revenue$3K−57.1% y/y
Operating income−$702K
Net income−$700K
Free cash flow$470K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Zoar Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
18/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
71
Issuance
56
Momentum
43
Quality
29
Accruals
29
Revisions
20
Value
18
Volatility
9

Growth (71): Sales and profits are climbing, and climbing faster than before.

Volatility (9): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ZOAR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZOAR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ZOAR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

ZOAR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.4×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
5.2×

Cheaper than 17% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
71.2%

Higher than 95% of US stocks

Return on assets
−17.3%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zoar Ltd. has a market value of $653.4M.

  • Revenue in the twelve months to 30 June 2026: $35K. The latest quarter shrank 57.1% year on year.

  • Net income over the same four quarters: $776K, a 2217.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$508K.

  • Shares outstanding: 180.0M.

  • Trailing P/E: 8.4×.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ZOAR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
ZOARZoar Ltd.$653.4M18
OGNOrganon & Co.$3.6B92
JANXJanux Therapeutics, Inc.*$606.3M73
OLMAOlema Oncology, Inc.*$611.8M25
KURAKura Oncology, Inc.*$613.4M53
ABUSArbutus Biopharma Corp.*$616.2M82
IAMIambic Therapeutics, Inc.*$621.4M1

* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.

Take a look at ZOAR’s peer groups, ranked by the model: consumer cyclical stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Zoar Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ZOAR

How does Ticker Nerd's model rank ZOAR?

As at 21 Nov 2026, Zoar Ltd. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (71 of 100).

What is the ZOAR stock forecast for 2030?

No analyst covering Zoar Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZOAR are extrapolating price history, which says nothing about the business.

What does Zoar Ltd. do?

Zoar Limited is a pharmaceutical company focused on developing and manufacturing complex active pharmaceutical ingredients and intermediates used in drug production. Through its operating businesses, the company also provides contract development and manufacturing services to pharmaceutical and biotechnology companies, supporting activities ranging from process development and formulation work to commercial-scale production.

Company

About Zoar Ltd.

Zoar Limited is a pharmaceutical company focused on developing and manufacturing complex active pharmaceutical ingredients and intermediates used in drug production. Through its operating businesses, the company also provides contract development and manufacturing services to pharmaceutical and biotechnology companies, supporting activities ranging from process development and formulation work to commercial-scale production. Its capabilities serve partners that require specialized chemistry, manufacturing expertise, quality-controlled production, and dependable supply of pharmaceutical inputs. Zoar Limited operates across the global pharmaceutical services market, where API manufacturers and contract development and manufacturing organizations play an important role in helping drug developers advance products from laboratory research toward broader production. The company’s business also encompasses pharmaceutical research and development activities associated with specialty therapeutic areas, including neurological, oncological, and immune-related conditions. Headquartered in Grand Cayman, the Cayman Islands, Zoar Limited combines pharmaceutical manufacturing, technical development, and outsourced production services within an industry that supports both established drug companies and emerging biotechnology businesses.

CEO Mr. Frank D. Heuszel Esq., J.D. · Hong Kong · https://zoarlimited.com